ORDOXTI
Live / Allowed — Published for opposition (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 03 Nov 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99475995
- Mark type
- Stylized text
- Filed
- 03 Nov 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- Jeffrey J. Scepanski
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Feb 2026 — ASSIGNED TO EXAMINER
- 03 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 03 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Nov 2025 — NEW APPLICATION ENTERED